Fida Biosystems
Hasse Hedeby has a diverse work experience spanning over several companies and roles. Hasse is currently the Chief Commercial Officer (CCO) at Fida Biosystems since September 2019, where they are responsible for commercializing novel technology for protein-binding characterization and protein quantification. Prior to this, in April 2019, Hasse Hedeby started their own company, Smiling Biotech.
In June 2019, Hasse Hedeby joined Bifrost Biolabs as a Board Member and acting CCO, a role they held until May 2022. Previously, they worked at ProZyme, Inc. where they served as the Director of ProZyme Europe Aps from October 2016 to March 2019. Their main responsibilities included establishing the European entity and driving sales in the Analytical Development labs of the Biopharma segment.
Before joining ProZyme, Inc., Hasse Hedeby worked as the EMEAI Business Team Leader for Seahorse Products at Agilent Technologies from November 2015 to September 2016. Prior to this, they served as the European Sales Director at Seahorse Bioscience from April 2009 to October 2015.
Hasse Hedeby's earlier experience includes working as an International Sales Manager at Upfront Chromatography A/S from April 2008 to March 2009. Hasse also held multiple roles at PerkinElmer, including Sales Leader Bio-discovery Nordic from January 2007 to March 2008, Sales Leader Denmark from November 2003 to December 2006, and Account Manager from August 2000 to October 2003.
Hasse Hedeby started their career at A/S Dansk Shell in April 1997, where they worked as a Technical Sales Support until July 2000.
Hasse Hedeby attended Aarhus University from 1989 to 1996, where they pursued a Master of Science degree in Chemistry. Following this, in 2002 to 2003, they enrolled at AVT Business School to study Management and obtained a Certificate in Business Administration.
Fida Biosystems
Fida Biosystems offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.